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1  | INTRODUC TION
Multiple myeloma (MM) is a malignant plasma cell disorder,1 af‐
fecting approximately 4 in every 100 000 individuals in Europe.2 
The past few decades have seen improved management of MM 
through multidisciplinary approaches. A European population‐based 
study reported an increase in 5‐year survival in patients with MM/
plasmacytoma from 29.8% in 1997‐1999 to 39.6% in 2006‐2008.3 
Furthermore, data from the Swedish Myeloma Registry suggested 
that a later year of diagnosis was associated with improved survival 
between 2008 and 2015 (hazard ratio [HR]: 0.84; 95% confidence 
interval [CI]: 0.77‐0.92; P < 0.05).4
Despite the positive trend in survival, response to anti‐MM ther‐
apy remains variable. Although some treated patients survive pro‐
gression‐free for more than 10 years,5 approximately 10% die within 
1 year of diagnosis.6,7 Furthermore, most patients will relapse and, 
because there is currently no effective cure, many will die of refrac‐
tory disease.8,9
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Abstract
Objectives: This study aimed to provide real‐world data on the characteristics and 
treatment of patients with multiple myeloma (MM) at the time of death.
Methods: The study was a retrospective patient chart review across France, 
Germany, Italy, Spain and the UK during 2016, and included patients who had died in 
the 3 months before the index date.
Results: Data from 786 patients were reviewed. At the time of death, 37% of patients 
were receiving active treatment, 12% were in a treatment‐free interval and 51% were 
receiving only supportive care. Death before and during active first‐line treatment 
was not uncommon (6% and 24% of patients, respectively) but these deaths were 
often not solely due to disease progression; factors such as renal failure and infection 
frequently played a role (in 30% and 20% of patients at first‐line, respectively). Most 
deaths at later lines were due to progressive disease. Cox model results suggested 
that early deaths were associated with advanced disease stage, high‐risk cytogenet‐
ics and poor response and relapse profiles.
Conclusions: These real‐world data could be used to help develop strategies for im‐
proving survival in patients with MM and to support management tailored to the 
stage of disease.
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A clear understanding of why patients with MM die is still lacking. 
Study populations often include a mixture of surviving patients and 
those who have died; there are few studies that focus on deceased 
patients. Mortality is usually attributed to combined effects of ac‐
tive MM and comorbid factors, but it is also linked to cytogenetic 
abnormalities that drive disease aggressiveness.10 More research is 
required to improve our understanding of mortality in patients with 
MM, particularly if it occurs soon after diagnosis. Improved under‐
standing could help to inform clinical decision‐making regarding the 
benefit‐risk profiles of therapeutic options and guide monitoring re‐
quirements for patients with MM at different stages of the disease 
and treatment pathway. Improved understanding of clinical events 
occurring before death related to MM might facilitate interventions 
to extend survival and improve tailored management at this critical 
stage.
This study was conducted to describe the characteristics, treat‐
ment patterns and outcomes before death associated with patients 
with MM.
2  | METHODS
2.1 | Study design
This was a retrospective chart review to describe treatment pat‐
terns, outcomes and healthcare resource use in European patients 
with symptomatic MM. During the second half of 2016, data were 
collected from the charts of patients in five European countries 
(EU5: France, Germany, Italy, Spain and the UK). Ethics commit‐
tee approval was received in Germany and Spain as per national 
regulations. The remaining countries did not have this requirement 
because the study was anonymous. The index date was the date 
on which physicians received study materials. Documentation oc‐
curredinJuneorJuly2016inFrance,ItalyandtheUK,andbetween
September and November 2016 in Germany and Spain.
Herein, we report a longitudinal analysis of a subgroup of pa‐
tients with MM identified as part of the full study. This subgroup of 
patients formed the “deceased population”: those who had died in 
the 3 months before the index date. The primary objective of this 
part of the study was to describe the treatment pathway from symp‐
tomatic MM diagnosis to death for this subgroup of patients.
2.2 | Eligibility
The recruitment process for participating physicians was designed 
to ensure that data were representative of clinical practice. Regional 
quotas and practice settings quotas (hospital types, office‐based for 
Germany) for the physicians were determined. Physicians, including 
oncologists, haematologists and onco‐haematologists, and intern‐
ists in Germany were solicited to participate in the study. The num‐
bers of physicians and patients per physician included in the study 
were based on the distributions in the respective countries, reflect‐
ing the methodology of a previously conducted chart review.11,12 
Documenting physicians were required to be personally responsible 
for initiating anti‐MM treatment in patients, and for the manage‐
ment of at least 15 patients with symptomatic MM per month (or 10 
for office‐based physicians in Germany). They were also required to 
have at least 3 years of clinical experience.
Patients were eligible for the “deceased patients” subgroup of 
the study if they had been diagnosed with symptomatic MM and 
had died, at the age of 18 years or over, in the 3 months prior to 
the index date. Such patients were included irrespective of other 
parameters, such as diagnosis date, profile, disease characteristics, 
treatment stage at death, treatment previously received, or previous 
participation in a clinical trial or early access programme.
2.3 | Analysis variables for the deceased population
Demographic data recorded at MM diagnosis included age, sex, 
height and weight. Details relating to diagnosis included diagnosis 
date, International Staging System (ISS) stage, circumstances of di‐
agnosis, cytogenetic abnormalities, comorbidities (including cardio‐
vascular disease, neuropathy and deep vein thrombosis) and history 
of skeletal‐related events.
Details relating to end of life included time from the end of the 
last treatment to death, cause of death and the last line of treatment 
received. Patients were classified according to whether they were 
receiving active anti‐MM treatment, were between treatment lines 
with further treatment planned, or were receiving supportive care 
with no further treatment planned. A patient was considered to be 
at a treatment line, for example first‐line (1L), if they were receiving 
active treatment at that line, receiving supportive care after having 
received active treatment at that line (with no further treatment 
planned), or were in a treatment‐free interval (TFI) after that treat‐
ment line with further treatment planned.
Data were analysed according to the treatment line received 
when patients died. It is important to appreciate that analysis of the 
data in this study was not intended to establish the relative risk of 
death at each treatment line, because the distribution of patients 
across lines was not reflective of the distribution observed in the 
overall MM population.
2.4 | Statistical analyses
The sample size was determined according to the 95% CI for de‐
scribing treatment lines of patients with symptomatic MM. Based 
on two patients dying in the past 3 months per physician (three pa‐
tients in the UK), the total anticipated sample size for the deceased 
population was 875 patients across the five countries. Aggregated 
data for the EU5 were weighted according to MM prevalence in each 
country.
An exploratory multivariate Cox model regression analysis was 
performed using backward selection with a significance threshold 
of P < 0.05 to explore factors associated with overall survival from 
diagnosis and from the initiation of 1L therapy. Models were de‐
veloped to include baseline characteristics, and baseline charac‐
teristics and outcomes at 1L treatment. The following variables at 
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diagnosisweretested:age(<65vs≥65years),ISSstage(IorIIvsIII),
presence of bone complications (yes vs no), renal dysfunction (yes 
vs no) and anaemia (yes vs no). The following variables at 1L were 
tested: Eastern Cooperative Oncology Group performance status 
at1L initiation (0‐1vs≥2), timetoprogression (TTP;≤15months
vs >15 months, based on the median TTP), very good partial re‐
sponse (VGPR) or better (yes vs no) and symptomatic progression 
after 1L (yes vs no). Additional variables tested included prior stem 
cell transplantation (yes vs no) and cytogenetic risk (high vs low). 
Included patients had initiated at least one treatment line and 
TA B L E  1   Deceased focus population: clinical and demographic characteristics
 
Treatment status at time of death
Before treatment 
(n = 50; 6%)
1L (n = 188; 
24%)
2L (n = 167; 
21%)
3L (n = 167; 
21%)
4L (n = 121; 
15%)
5L (n = 96; 
12%)
Time elapsed since diagnosis (months)
Mean 2.6 11.0 30.1 49.0 61.4 87.7
Range 0‐48 0‐112 1‐150 2‐220 13‐183 9‐256
Age group at diagnosis (%)
<65 y 5 18 17 38 54 57
65‐75 y 15 21 45 40 37 34
>75 y 80 61 38 22 10 9
Age at diagnosis (y)
Mean 81.0 75.4 72.2 66.7 63.7 62.1
Median 83.0 78.0 74.0 67.0 64.0 63.0
Range 53‐96 38‐96 41‐91 32‐91 39‐83 40‐83
ISS stage at diagnosis (%)
I 5 3 8 14 13 26
II 5 21 21 29 32 24
III 80 69 63 49 47 38
Unknown 10 8 9 9 9 12
Sex (%)
Male 56 54 56 54 57 52
Female 44 46 44 46 43 48
Transplantation status (%)
SCT 0 10 21 42 51 62
No SCT 100 90 79 58 49 38
Cytogenetic risk status (%)a
High 6 21 27 30 21 18
Low 9 17 20 19 27 45
Unknown 84 62 53 52 53 37
Comorbidity (%)
Deep vein thrombosis 42 27 18 14 10 10
Neuropathy 18 15 11 12 10 16
Significant cardiovascular disease 86 53 34 23 16 20
Skeletal‐related event 20 19 25 30 32 22
ECOG score at 1L therapy initiation (%)b
0‐1 NA 33 61 71 81 73
2 NA 67 39 29 19 27
Note: Total patient number is reported here as 789, rather than 786, owing to weighting of the data.
Low cytogenetic risk was defined as being negative for all three cytogenetic abnormalities.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System; L, treatment line; NA, not available; SCT, stem cell 
transplantation.
aHigh cytogenetic risk was defined as having t(4;14), t(14;16) or del(17p). 
bECOG score at 1L therapy initiation was measured approximately 1 mo after diagnosis. 
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progressed after 1L. Patients with missing or unknown values for 
these variables were excluded from the analysis. No formal hypoth‐
eses were tested. Categorical data were summarised as the num‐
ber and percentage of patients in each category. Continuous data 
were summarised as the mean, median, minimum and maximum. 
Missing or incomplete data were marked as unavailable if they could 
not be captured even after communication with the participating 
physician.
3  | RESULTS
3.1 | Physician and patient characteristics
Across the countries, 391 physicians from 391 centres participated 
(France, 82; Germany, 91; Italy, 85; Spain, 75; UK, 58). Almost all 
physicians (99.5%) were oncologists or haematologists. The charts of 
786 deceased patients were reviewed (France, 139; Germany, 171; 
Italy, 171; Spain, 138; UK, 167). The clinical and demographic char‐
acteristics of these patients at diagnosis are summarised in Table 1 
(note that the distribution of patients across treatment lines does 
not reflect the overall population with MM).
3.2 | Treatment status at time of death
At the time of death (ie study inclusion), 37% of patients were receiv‐
ing active anti‐MM treatment (6% in remission, 31% not in remis‐
sion). Another 12% were in a TFI, with further treatment planned 
(4% in remission, 9% not in remission). The remaining 51% were re‐
ceiving only supportive care (ie no active anti‐MM treatment; 3% in 
remission, 48% not in remission).
Of the 786 included patients, who died in the 3 months prior 
to the index date, approximately one‐quarter (24%) were at 1L at 
the time of death (Figure S1). Similar proportions of patients were 
at second or third line (2L, 3L), with fewer at fourth or fifth line 
(4L, 5L). For those who died during a TFI, the earlier the treatment 
line, the more likely it was that further treatment was planned 
(Table 2).
At diagnosis, there were some notable differences in the char‐
acteristics of patients who subsequently died at early (ie 1L or 2L) 
versus later treatment lines (ie 4L or 5L) (Table 1). For example, 
those reaching later lines were typically younger (Figure 1) and at a 
lower ISS stage at diagnosis (Table 1). Patients reaching later lines 
also had a lower Eastern Cooperative Oncology Group score and 
carried a lower morbidity burden (Table 1).
3.3 | Survival
The mean duration of survival from the end of the last treatment 
line tended to decrease with increasing line up to and including 4L 
(Figure 2A), indicating that patients dying at later lines had shorter 
treatment‐free periods leading up to death. The median overall sur‐
vival was 30 months (Figure 2B). As expected, patients dying at later 
treatment lines survived for longer overall, although the survival curve 
reached a plateau for a small proportion of patients who died at 1L, 
indicating that a subset of patients may live for many years without 
requiring treatment beyond 1L.
TA B L E  2   Situation of death, by treatment line
 
Treatment status at time of death
Overall 
(n = 789)
Prior to treatment 
(n = 50; 6%)
1L (n = 188; 
24%)
2L (n = 167; 
21%)
3L (n = 167; 
21%)
4L (n = 121; 
15%)
5L (n = 96; 
12%)
During active treatment (%) 37 0 47 35 38 35 41
During TFI (%) 63 100 54 65 62 65 59
On supportive care (%) 51 97 34 49 52 55 55
Further treatment planned (%) 12 3 19 16 10 10 5
Note: Categorisation by treatment line includes patients who died during or following each treatment line, before moving on to the subsequent line. 
Total patient number is reported here as 789 rather than 786, owing to weighting of the data.
Abbreviations: L, treatment line; TFI, treatment‐free interval.
F I G U R E  1   Age at time of death, by treatment line. 
Categorisation by treatment line includes patients who died during 
or following each line, before moving on to the subsequent line. 
Total patient number is reported here as 789, rather than 786, 
owing to weighting of the data. L, treatment line
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(n = 96)
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Median age at time 
of death (years) 78.0 76.0 71.0 69.0 70.0
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3.4 | Cause of death
For two‐thirds (67%) of patients, death was primarily attributed to dis‐
ease progression (which was defined as symptomatic relapse, increases 
in M‐protein or free light chain levels) (Figure 3A). Among those whose 
death was attributed to disease progression, 44% also had other causes 
listed. These were primarily renal failure (59%) and infection (28%).
Across treatment lines, deaths were often not solely due to 
disease progression (Figure 3B). Factors such as renal failure and 
infection also played a role (in 30% and 20% of patients at 1L, re‐
spectively). The later the treatment line at which a patient died, 
the greater the likelihood that disease progression was the primary 
cause of death (Figure 3B). The proportion of patients whose death 
was attributed to disease progression increased from 40% of those 
who died before 1L, to 50% at 1L, 72% at 3L and 84% at 5L. This pat‐
tern for the contribution of disease progression to death was seen 
regardless of patient age group at death (data not shown).
Renal failure and infection were the next most common causes 
of death across all treatment lines (Figure 3B). This was true across 
all age groups; however, for patients in the age groups 65 years and 
under or 65‐75 years at death, infection and renal failure became 
less likely to be the primary cause of death as therapy line increased, 
whereas the opposite trend was seen for patients aged over 75 years 
(data not shown).
The proportion of patients with at least one other cause of death 
in addition to disease progression also tended to decrease with in‐
creasing treatment line: 73%, 53%, 48%, 42%, 30% and 39%, respec‐
tively. The proportion of patients whose death was linked to disease 
progression was higher in those receiving supportive care (78%) than 
those on active treatment or in a TFI with further treatment planned 
(57% and 52%, respectively).
For the group of patients who died while in remission (12%), 
deaths were still related to factors that may be associated with MM 
or its treatment, including disease progression (10%), renal failure 
(15%) or infection (22%) (Figure 3C).
3.5 | Factors associated with death in MM
An exploratory Cox model regression analysis was conducted using 
data from 338 patients after excluding the following patients: pa‐
tients with missing or unknown values for one or more variables; 
patients who had not initiated at least one treatment line; or patients 
who had not progressed after 1L (Figure 4). This analysis found that 
overall survival from diagnosis was significantly increased in patients 
with low cytogenetic risk (vs high risk), ISS stage I or II at diagnosis (vs 
stageIII)andaTTPofover15monthsat1L(vs≤15months).Incon‐
trast, overall survival was significantly reduced for patients whose 
best response was partial or worse at 1L (vs VGPR or better) and 
for patients with symptomatic relapse at 1L (vs non‐symptomatic re‐
lapse). Similar results were obtained regarding patient survival from 
the initiation of 1L therapy, and when assessing baseline variables 
only (data not shown).
4  | DISCUSSION
Most data relating to mortality in MM come from clinical trials, in 
which populations are subject to eligibility criteria that often exclude 
F I G U R E  2   A, Patient flow through 
the treatment pathway. Categorisation 
by treatment line includes patients who 
died during or following each line, before 
moving on to the subsequent line. Total 
patient number is reported here as 789, 
rather than 786, owing to weighting of the 
data. L, treatment line. B, Overall survival 
according to treatment line at time of 
death. Black line and data labels show 
the median overall survival in months. L, 
treatment line
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patients with major comorbidities, thus confounding analysis of cir‐
cumstances of death. To the best of our knowledge, this is the first 
study to evaluate data from deceased patients with MM in Europe. 
The large size of this study, and the setting of care in oncology/hae‐
matology units, allowed us to examine both patient pathways and 
the association of patient and disease factors with death, in patients 
who died in 2016.
Despite the increasing availability of effective treatment options, 
relapse remains inevitable for most patients with MM, and an unmet 
medical need exists with regard to the unchanged prevalence of 
early deaths (approximately 10%).7,9,13 Owing to the study design, it 
is not possible to provide mortality per treatment line because the 
study population is not representative of the distribution of patients 
across treatment lines in the overall MM population. Nevertheless, 
our data suggest that death during active 1L treatment remains a key 
issue; 47% of deaths at 1L were during active treatment. This study 
adds to a chart review conducted in 2014 that reported high losses 
of patients along the treatment pathway; in the previous review, 
39% of patients did not go on to receive 2L treatment, and 62% did 
not receive 3L treatment.11,12
Death during active treatment is not only an issue at 1L; a sub‐
stantial proportion of patients at each line died while on active treat‐
ment (more than one‐third of patients overall). Half of deaths at 1L 
were due to MM progression, and the prognostic influence of depth 
of response to, and early relapse from, 1L treatment is borne out by 
the Cox model results. This underscores the considerable contribu‐
tion that disease progression makes to death. Nevertheless, other 
causes of death that may be related to MM and associated treatment 
were also important, such as renal failure (30%) and infection (20%), 
particularly at early treatment lines. The proportion of deaths due 
to disease progression increased at later lines, but renal failure and 
infections remained significant contributors to cause of death.
The Cox model results also highlight the fact that deaths can be 
associated with disease‐related factors not captured by the ISS, such 
as cytogenetic risk and time to progression. Indeed, approximately 
one‐quarter of patients who died at 1L or 2L had an ISS stage of I 
F I G U R E  3   Causes of deatha (A) overall 
and (B) by line, and (C) overall stratified 
by response status at time of death. Total 
patient number is reported here as 789, 
rather than 786, owing to weighting of the 
data. aMultiple factors may be captured as 
cause of death. L, treatment line
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or II. It is established that the ISS is not the strongest available pre‐
dictive tool, and it has recently been revised to include serum lac‐
tate dehydrogenase and chromosomal abnormalities, which improve 
prognostic power.14
Although sparse, there are other real‐world data available on 
factors associated with mortality in MM in Europe. A recent study 
found that over four‐fifths of deaths in a cohort of patients with MM 
from Germany could be attributed to the underlying malignancy 
and associated complications, with approximately half of those my‐
eloma‐related deaths attributed to the malignancy itself, 15% to in‐
fections and 13% to renal disorders.15 A study using the Connect® 
MM Registry identified predictors of early death (defined as death 
within the first 6 months after diagnosis).9 These predictors included 
age over 75 years, worse performance status, adverse cytogenetics, 
lower mobility score, higher ISS stage, lower platelet count and pre‐
vious history of hypertension.9 A study using the Danish National 
MM Registry found that patients with newly diagnosed MM had 
increased comorbidities compared with the general population, par‐
ticularly in the year preceding diagnosis; those with any registered 
comorbidity had increased mortality compared with those without a 
comorbidity (HR: 1.6).16 In a population‐based cohort study, the im‐
pact of comorbidities on early mortality was analysed over a 31‐year 
period.17 Comorbidities were found to have an independent impact 
on early mortality: at different time points, renal failure, respiratory 
disease, liver disease and hepatitis C infection were each associated 
with early mortality.17 Similarly, a large chart review across seven 
European countries found that comorbidities reduced continuation 
to the next treatment line.12 These studies suggest that disease‐re‐
lated prognostic variables, such as ISS stage and cytogenetic risk,18 
are not the only determinants of death early in the disease course. 
This is consistent with our data, which showed that there were fewer 
deaths related to disease progression at earlier treatment lines than 
at later treatment lines.
Many patients in this study died while their disease was consid‐
ered to be in remission, and yet deaths were often related to causes 
that may be associated with MM and its treatment. A possible expla‐
nation for this observation is that despite exhibiting a therapeutic 
response to each treatment line, patients were nonetheless subject 
to a cumulative disease burden, contributed to by multiple relapses, 
drug resistance and increasingly aggressive biology. Thus, in order 
to maximise the benefits of increasingly effective MM therapies, a 
better understanding is needed of how to optimise the management 
of MM for patients who are in remission. Reducing the risk of renal 
damage, and immune and bone marrow suppression, should be given 
due attention in the overall care of these patients.19,20 Additionally, 
sufficient guidance needs to be produced to support physicians in 
this aspect of treating patients with MM.
Our study also identified patients who died before 1L therapy. 
These individuals were typically elderly and had advanced disease 
at diagnosis. Nearly all (97%) of these patients did not receive ac‐
tive anti‐MM treatment but instead received supportive care only. 
Further work is required to improve the prognosis of these patients; 
for example, if poor organ function and comorbidities are the result of 
MM, opportunities for effective management may include institution 
of anti‐MM therapy with careful dose and schedule adjustment.20
A strength of this real‐world study is that findings should be re‐
flective of clinical practice; the five countries included in the study 
were selected because of their large populations, representing the 
majority of patients treated in Europe. These populations offer a 
broad and generalisable data set because of the differences in health 
F I G U R E  4   Factors associated with overall survival after MM diagnosis. Results of an exploratory multivariate Cox model regression 
analysis of overall survival from MM diagnosis using data from 338 patients. The analysis included variables at baseline and outcomes at 1L 
treatment for patients who had initiated at least one treatment line and progressed after 1L. Patients with missing or unknown values for the 
variables tested were excluded from the analysis. High cytogenetic risk was defined as having t(4;14), t(14;16) or del(17p). Low cytogenetic 
risk was defined as being negative for all three cytogenetic abnormalities. CI, confidence interval; ECOG, Eastern Cooperative Oncology 
Group; HR, hazard ratio; ISS, International Staging System; L, treatment line; MM, multiple myeloma; PR, partial response; SCT, stem cell 
transplantation; TTP, time to progression; VGPR, very good partial response
Age at diagnosis: ≥65 years (vs <65 years)
Anaemia at diagnosis: no (vs yes)
Bone pain at diagnosis: no (vs yes)
Cytogenetic risk: low (vs high)
ECOG performance status at
 1L-treatment initiation ≥2 (vs 0–1)
ISS stage I or II at diagnosis (vs III)
PR or worse at 1L (vs VGPR or better)
Renal dysfunction at diagnosis: yes (vs no)
SCT: yes (vs no)
Symptomatic progression after 1L
 (vs non-symptomatic)
TTP > 15 months (vs ≤15 months)
HR
1.74
0.89
0.97
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0.99–1.52
0.16–0.26
0.0 0.5 1.0 1.5 2.0 2.5 3.0
Hazard ratio
Favours deathFavours survival
114  |     MOHTY eT al.
systems and drug access among the countries. It is, however, chal‐
lenging to compare the characteristics of the study population with 
those from other European population‐based studies owing to dif‐
ferences in the parameters reported.16,21 A relatively high propor‐
tion of patients scored III using the ISS at diagnosis compared with 
other studies,16,21 although high ISS stages are associated with poor 
survival and would be expected in a population of now deceased 
patients.22 Furthermore, only one‐quarter of patients had a history 
of skeletal‐related events; this is lower than would be expected be‐
cause bone disease occurs in 80% of patients with newly diagnosed 
MM.23 This may be explained by the specific definition of skeletal‐
related events (pathologic fracture, spinal cord compression, and 
radiation or surgery to bone); “bone disease” is likely interpreted by 
physicians as a more general term.
Potential limitations of the study include the possibility of data 
inconsistencies resulting from site‐specific management differences, 
such as variation in clinical interpretation of disease progression and re‐
mission. Interpretation of the data must consider the recording of mul‐
tiple “causes” of death (primary, secondary; eg renal failure associated 
with MM progression), and the generalisability of the exploratory Cox 
model regression analyses may be limited by the fact that they included 
data from fewer than half of study patients. Only deceased patients 
were evaluated; hence, the characteristics reported are specific to that 
population. Finally, it is important to note that the characteristics of 
patients at each treatment line were taken from separate populations.
In conclusion, this real‐world study of patients confirms that 
deaths at early treatment lines remain a key challenge in MM man‐
agement. It also highlights that death during early treatment lines 
is often not due to disease progression, and death commonly oc‐
curs during active treatment, indicating a need for improvements 
in supportive care. As patients reach later lines, death is more 
typically related to progression, owing to treatment resistance.24 
Understanding factors associated with death in MM could help to 
increase the proportion of patients who reach later lines and inform 
new management approaches for improving patient survival.
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